Ficolin-3, Human, ELISA kit
Ficolins are a group of proteins containing both a collagen-like domain and a fibrinogen-like domain. Three forms of Ficolin have been identified in humans: Ficolin-1 (M-ficolin), Ficolin-2 (L-ficolin) and Ficolin-3 (H-ficolin 3). Ficolin-3, also known as Hakata-antigen or H-ficolin, is composed by a collagen-like strand and three C-terminal recognition domains which bind to acetyl groups on microbial surfaces such as GlcNAc or GalNAc. Ficolin-3 is synthesized both in the liver, from where it is secreted into the blood circulation, and in the lung. Similar to MBL and Ficolin-2, Ficolin-3 relies on MBL-associated serine protease 2 (MASP-2) for activation of the complement system. After binding of Ficolin-3/MASP-2 complexes to microbial surfaces, MASP-2 sequentially cleaves C4 and C2, thereby generating the C3 convertase C4bC2b, which finally leads to opsonization and direct lysis of pathogens and recruitment of inflammatory cells.
Ficolin-3 is present in serum at mean concentration of 15 µg/ml, with only minor variations. Ficolin-3 was present in all sera from more than 150,000 individuals tested, except in some systemic lupus erythromatosis patients. Approximately 5% of systemic lupus erythromatosis patients were found to be Ficolin-3 negative, probably owing to the presence of anti-Ficolin-3 autoantibody. In 398 patients with other autoimmune diseases, Ficolin-3 was always present. In liver disease the serum levels decreased with increasing severity of cirrhosis.
Ficolin-3 bound to a population of late apoptotic cells, while a strong and uniform binding to necrotic cells was observed. The binding properties differed from those of MBL and Ficolin-2. Ficolin-3 binding to late apoptotic cells resulted in a significant increase in adhesion/uptake by macrophages.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA